---
title: "bite_rrmm"
date: "2024-07-27"
tags:
  - building
---

> [!NOTE]
> ğŸŒ± created from: [[bite]]

# BiTE RRMM

- BCMA, also known as tumor necrosis factor receptor superfamily 17 (TNFRSF17) or CD269, is a type III transmembrane glycoprotein that is expressed on mature B-lymphocytes, overexpressed on malignant PCs, and absent in non-hematological tissues.

  - åˆç¨±è…«ç˜¤å£æ­»å› å­å—é«”è¶…å®¶æ— 17ï¼ˆTNFRSF17ï¼‰
  - æˆ– CD269
  - æ˜¯ä¸€ç¨® III å‹è·¨è†œç³–è›‹ç™½
  - åœ¨æˆç†Ÿçš„ B æ·‹å·´ç´°èƒä¸Šè¡¨é”
  - åœ¨æƒ¡æ€§æ¼¿ç´°èƒä¸Šéåº¦è¡¨é”
  - åœ¨éè¡€æ¶²çµ„ç¹”ä¸­å‰‡ä¸å­˜åœ¨

- [[teclistamab.md|Teclistamab]] CD3/BCMA R/R MM after â‰¥4 prior LOT, including an IMiD, PI, and anti-CD38 mAb (2022)
- [[talquetamab.md|Talquetamab]] CD3/[[gprc5d.md|GPRC5D]] R/R MM after â‰¥4 prior LOT, including an IMiD, PI, and anti-CD38 mAb (2023)
  - [[monumental-1.md|MonumenTAL-1]]
- [[elranatamab.md|Elranatamab]] CD3/BCMA R/R MM after â‰¥4 prior LOT, including an IMiD, PI, and anti-CD38 mAb (2023)

- [[cart_or_bite_in_mm.md|CART or BiTE in MM]]
- Extramedullary Disease: Worse Prognosis

- [[toxicity_management_in_bispecific_antibiotics_in_multiple_myeloma.md|Toxicity management in bispecific antibiotics in multiple myeloma]]

[[frequency_and_duration_of_bispecific_antibiotics.md|Frequency and Duration of bispecific antibiotics]]
